Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd (FREDUN) last reported results for the quarter ended Jun 2026, with sales of ₹228 crore and net profit of ₹13 crore. The stock last traded at ₹1,369, a market capitalisation of ₹2,264 crore, on a P/E of 51.6. Over the past 52 weeks the stock has ranged between ₹454 and ₹1,600. Figures are as of 6 Oct 2026 and are not real time.
Fredun Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹1,369
- Market cap
- ₹2,264 cr
- Stock P/E
- 51.6
- Book value
- ₹170
- ROE
- 15.6%
- ROCE
- 21.3%
- Dividend yield
- 0.02%
- 52w high / low
- 1600/454
Metrics as of 6 Oct 2026. Not real time.
Track Fredun Pharmaceuticals Ltd
Cruxal reads every Fredun Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Fredun Pharmaceuticals Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 40%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 65%
- 10 Years
- 66%
- 5 Years
- 52%
- 3 Years
- 63%
- 1 Year
- 191%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- 16%
Fredun Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹228 cr, up 90.0% from ₹120 cr a year earlier. Net profit was ₹13 cr, up 85.7% year on year.
| ₹ crore | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 0 | 167 | 120 | 145 | 161 | 213 | 228 |
| Expenses | 0 | 150 | 103 | 123 | 135 | 184 | 196 |
| Operating profit | 0 | 17 | 17 | 22 | 26 | 29 | 33 |
| OPM % | — | 10% | 14% | 15% | 16% | 14% | 14% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 8 | 7 | 8 | 11 | 14 | 9 |
| Depreciation | 0 | 2 | 1 | 2 | 2 | 3 | 4 |
| Profit before tax | 0 | 7 | 9 | 13 | 14 | 11 | 21 |
| Tax % | — | 17% | 25% | 26% | 25% | 4% | 36% |
| Net profit | 0 | 6 | 7 | 9 | 10 | 11 | 13 |
| EPS (₹) | 0.00 | 4.23 | 4.77 | 6.64 | 6.51 | 6.57 | 7.96 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Fredun Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
| Sales | 454 | 635 | 748 |
| Operating profit | 52 | 91 | 110 |
| OPM % | 12% | 14% | 15% |
| Net profit | 20 | 33 | 44 |
| EPS (₹) | 13.90 | 19.89 | 27.68 |
TTM is the trailing twelve months to the most recent quarter.
Fredun Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2025 | Mar 2026 |
|---|---|---|
| Equity capital | 5 | 5 |
| Reserves | 137 | 273 |
| Borrowings | 167 | 222 |
| Other liabilities | 179 | 142 |
| Total liabilities | 487 | 642 |
| Fixed assets | 53 | 118 |
| CWIP | 0 | 0 |
| Investments | 2 | 2 |
| Other assets | 433 | 522 |
| Total assets | 487 | 642 |
As reported by the company. Total assets equal total liabilities by construction.
Fredun Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2025 | Mar 2026 |
|---|---|---|
| Cash from operations | -17 | 12 |
| Cash from investing | -6 | -74 |
| Cash from financing | 27 | 121 |
| Net cash flow | 4 | 60 |
| Free cash flow | -23 | -62 |
| CFO / operating profit | -32% | 13% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Fredun Pharmaceuticals Ltd operating ratios
| Per year | Mar 2025 | Mar 2026 |
|---|---|---|
| ROCE % | — | 21% |
| Debtor days | 142 | 53 |
| Inventory days | 267 | 219 |
| Days payable | 161 | 71 |
| Cash conversion cycle | 248 | 201 |
| Working capital days | 76 | 78 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Fredun Pharmaceuticals Ltd shareholding pattern
Promoters held 44.57% at Jul 2026, down from 48.93% at Sep 2025. FIIs 1.06% and DIIs 2.94%.
| % held | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Jul 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 48.93% | 48.93% | 48.93% | 48.93% | 43.06% | 44.17% | 44.57% | 44.57% |
| FIIs | 0.00% | 0.00% | 0.00% | 0.01% | 0.46% | 1.06% | 1.06% | 1.06% |
| DIIs | 1.59% | 1.59% | 1.59% | 1.61% | 3.48% | 2.83% | 2.94% | 2.94% |
| Public | 49.47% | 49.47% | 49.49% | 49.46% | 53.00% | 51.94% | 51.45% | 51.43% |
| No. of shareholders | 8,121 | 7,976 | 7,906 | 8,120 | 8,765 | 8,338 | 8,903 | 9,598 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Cruxal coverage of Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd corporate filings
- Fredun Pharmaceuticals issues press release on October 8, 2026Company Updatelow impact
Cruxal's analysis: Fredun Pharmaceuticals Limited, a small-cap company with a market cap of approximately…
Read the full analysis - Fredun Pharmaceuticals announces revised allotment of 182,400 equity shares under Regulation 30 (LODR)Company Updatelow impact
Cruxal's analysis: On October 5, 2026, Fredun Pharmaceuticals Ltd disclosed a revised allotment of 182,400…
Read the full analysis - Fredun Pharmaceuticals Limited completes allotment of 1,82,400 equity shares via warrant conversion, post bonus issue, indicating ongoing capital restructuringCompany Updatemedium impact
Cruxal's analysis: Fredun Pharmaceuticals Limited has issued 1,82,400 new equity shares of Rs. 10 each…
Read the full analysis - Fredun Pharmaceuticals Allots Equity Shares via Warrant ConversionCompany Updatelow impact
Cruxal's analysis: Fredun Pharmaceuticals Ltd announced the allotment of equity shares on October 3, 2026…
Read the full analysis - Fredun Pharmaceuticals completes allotment of 1,82,400 equity shares to warrant holders following conversion and bonus issueOthersmedium impact
Cruxal's analysis: Fredun Pharmaceuticals has issued 1,82,400 new equity shares of Rs. 10 each, following…
Read the full analysis - Intimation of Trading Window ClosureInsider Trading / SASTlow impact
- Fredun Pharmaceuticals Ltd announces revised allotment of equity shares upon warrant conversionCompany Updatelow impact
Cruxal's analysis: The company has issued a revised notification regarding the allotment of equity shares…
Read the full analysis - Fredun Pharmaceuticals completes conversion of 1.20 lakh warrants into 3.61 lakh equity sharesCompany Updatemedium impact
Cruxal's analysis: Fredun Pharmaceuticals Limited has successfully completed the conversion of 1.20 lakh…
Read the full analysis - Fredun Pharmaceuticals Ltd releases press statement dated 22-09-2026Company Updatelow impact
Cruxal's analysis: Fredun Pharmaceuticals Ltd has issued a press release dated September 22, 2026, under…
Read the full analysis - Fredun Pharmaceuticals Ltd allots 271,200 equity shares upon conversion of warrantsCompany Updatelow impact
Cruxal's analysis: Fredun Pharmaceuticals has completed the allotment of 271,200 equity shares following the…
Read the full analysis - Fredun Pharmaceuticals completes conversion of 90,400 warrants into 2,71,200 equity sharesOthersmedium impact
Cruxal's analysis: Fredun Pharmaceuticals Limited has successfully concluded the conversion of 90,400…
Read the full analysis - Fredun Pharmaceuticals Ltd releases revised press release under Regulation 30Company Updatelow impact
Cruxal's analysis: Fredun Pharmaceuticals has issued a revised press release in compliance with Regulation…
Read the full analysis - Fredun Pharmaceuticals Ltd releases routine press release under Regulation 30Company Updatelow impact
Cruxal's analysis: Fredun Pharmaceuticals Ltd has issued a press release under Regulation 30 of the SEBI…
Read the full analysis - Fredun Pharmaceuticals Ltd issues routine press release under Regulation 30Company Updatelow impact
Cruxal's analysis: Fredun Pharmaceuticals has filed a press release under Regulation 30 of the SEBI (LODR)…
Read the full analysis - Fredun Pharmaceuticals Limited issues press release dated 04.09.2026Company Updatelow impact
Cruxal's analysis: Fredun Pharmaceuticals Limited has issued a press release on 04.09.2026. The filing is a…
Read the full analysis - Fredun Pharmaceuticals Ltd receives approval for trading of equity shares on the National Stock Exchange (NSE)Company Updatelow impact
Cruxal's analysis: Fredun Pharmaceuticals has received formal permission to trade and admission of its…
Read the full analysis - Fredun Pharmaceuticals Reports Strong Q1 FY27 Growth with 90% Revenue Surge and Strategic Expansion PlansCompany Updatehigh impact
Cruxal's analysis: Fredun Pharmaceuticals Limited delivered robust Q1 FY27 results, with total income…
Read the full analysis - Fredun Pharmaceuticals Ltd reports no deviation in fund utilization for quarter ended June 30, 2026Company Updatelow impact
Cruxal's analysis: Fredun Pharmaceuticals has filed a statement confirming that there has been no deviation…
Read the full analysis - Fredun Pharmaceuticals Ltd files Monitoring Agency Report dated 14.08.2026Company Updatelow impact
Cruxal's analysis: Fredun Pharmaceuticals has submitted a routine Monitoring Agency Report as part of its…
Read the full analysis - Fredun Pharmaceuticals Limited releases audio recording of Q1 FY27 earnings conference callCompany Updatelow impact
Cruxal's analysis: Fredun Pharmaceuticals Limited has formally disclosed the audio recording of its Q1 FY27…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.